Sanofi India and Sanofi Healthcare India, and Cipla have announced an exclusive partnership for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India.

As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium, a leading brand in the anti-epileptic medication category. 

While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Mumbai-based pharmaceutical company Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programmes to expand access to these treatments for patients who need them.

Rodolfo Hrosz, Managing Director, Sanofi India said “Sanofi India’s CNS products are leaders in their respective categories. These well-established brands already improve lives of many patients across urban centres in the country. Cipla’s wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across all India.” 

Achin Gupta, Chief Executive Officer – One India Business, Cipla said “Central Nervous System is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address unmet needs of patients.”